スターガルト病治療薬の世界市場-2023年～2030年

市場概要

スターガルト病治療薬の世界市場は、2022年に1億9,710万米ドルに達し、2030年には13億8,560万米ドルに達するなど、有利な成長が予測されています。世界のスターガルト病治療薬市場は、予測期間中（2023～2030年）に28.8%のCAGRを示すと予測されています。

スターガルト病は遺伝性の眼疾患です。スターガルト病は小児期から青年期にかけて発症することが多く、時間の経過とともに視力低下が進行します。現在、スターガルト病に対する治療法は確立されていないが、病状をコントロールし、発症を食い止めるための治療戦略の開発には大きな進歩が見られます。

市場力学

治療法の進歩が予測期間中の世界のスターガルト病治療薬市場の成長を後押ししています

治療法を臨床研究へと発展させ、それを必要とする患者に届けるために、Opsis Therapeuticsが最近設立されました。1つの層は、視覚を可能にする光受容体の前駆体として機能します。この層の幹細胞は移植後に光受容体に成長します。

成熟した網膜色素上皮（RPE）細胞は、光受容体に食物を供給し、老廃物を除去します。パッチの構造の骨格は薄いプラスチックフィルムです。細胞は遮蔽され、層は生分解性ゲルによってつなぎ合わされます。

幹細胞療法は世界のスターガルト病治療薬市場に成長機会をもたらす

損傷した網膜細胞を修復するために幹細胞を利用することも、開発分野の一つです。網膜色素上皮（RPE）細胞は、患者自身の細胞から作製した人工多能性幹細胞（iPSC）から開発し、眼球に再移植することができます。動物実験では、この方法は、病気や損傷を受けた細胞を置き換えるのに有望であることが示されており、現在、人における安全性と有効性を確認するための臨床試験が行われています。

COVID-19の影響分析

COVID-19の大流行はスターガルト病治療薬市場に大きな影響を与えています。患者募集の制限、ヘルスケア施設へのアクセスの制限、COVID-19へのリソースの優先順位付けのため、パンデミックは世界中で現在行われている臨床試験を中断させました。この挫折は、スターガルト病に対する治療法の臨床試験の開発を遅らせ、規制当局の承認と市場参入に必要な時間を増加させている可能性があります。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争がスターガルト病治療薬市場に与える影響は複雑かつ多面的です。紛争の影響を直接受けた地域では、病院、診療所、研究機関などのヘルスケア施設が破壊されたり、アクセス不能になったりしている可能性があります。スターガルト病治療薬に関するヘルスケアの提供、臨床試験の実施、または調査の実施能力は、この混乱によって影響を受ける可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 調査活動の活発化
  • 抑制要因
    • 専門家の不足
  • 機会
    • 治療の進歩
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 薬剤タイプ別

• LBS-008
• エミクススタット

第10章 年齢層別

• 小児
• 成人

第11章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Kubota Pharmaceutical Holdings Co., Ltd.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Stargazer Pharmaceuticals Inc
• Sanofi S.A.
• Alkeus Pharmaceuticals Inc
• Astellas Pharma Inc.
• CHABiotech CO., Ltd.
• ReVision Therapeutics, Inc.
• Lin BioScience, Inc.
• Biogen Inc.
• F. Hoffmann-La Roche AG

第15章 付録

Market Overview

The Global Stargardt Disease Therapeutics Market reached US$ 197.1 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,385.6 million by 2030. The global Stargardt Disease Therapeutics market is expected to exhibit a CAGR of 28.8% during the forecast period (2023-2030).

The part of the retina that is responsible for clear, central vision, the macula, is harmed by Stargardt disease, an inherited eye condition. It often first appears throughout childhood or adolescence and over time may cause progressive visual loss. While there is now no treatment for Stargardt disease, there has been substantial advancement in the creation of therapeutic strategies to control the condition and maybe halt its development.

Market Dynamics

Advancement in Therapy Is Boosting The Global Stargardt Disease Therapeutics Market Growth During The Forecast Period.

To advance the therapy into and through a clinical study and out to the patients who need it, Opsis Therapeutics was recently founded, two layers make up the patch. One layer will act as a precursor for photoreceptors that enable vision. The stem cells in this layer will develop into photoreceptors after transplantation.

Mature retinal pigment epithelial (RPE) cells, which provide food and waste removal for photoreceptors, will make up the other layer. The backbone of the patch's structure will be a thin plastic film. The cells will be shielded and the layers will be held together by a biodegradable gel.

Stem Cell Therapy Provides The Global Stargardt Disease Therapeutics Market Growth Opportunities

Utilizing stem cells to repair damaged retinal cells is another area of development. Retinal pigment epithelium (RPE) cells can be developed from induced pluripotent stem cells (iPSCs) produced from a patient's own cells and re-implanted into the eye. In animal research, this method has shown promise for replacing sick or damaged cells, and clinical trials are now being conducted to determine its safety and effectiveness in people.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the Stargardt disease therapeutics market. Due to limitations on patient recruitment, restricted access to healthcare facilities, and the prioritization of resources towards COVID-19, the pandemic has disrupted current clinical trials across the globe. This setback might have slowed down the development of clinical trials for treatments for Stargardt's illness, thereby increasing the amount of time needed for regulatory clearances and market entry.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the Stargardt disease therapeutics market is complex and multifaceted. Healthcare facilities, including as hospitals, clinics, and research institutes, may have been destroyed or made inaccessible in areas directly impacted by the conflict. The capacity to deliver healthcare, perform clinical trials, or conduct research on Stargardt Disease Therapeutics may be impacted by this disruption.

Segment Analysis

The global Stargardt disease therapeutics market is segmented based on drug type, age group, distribution channel, and region.

The LBS-008 Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.

The LBS-008 segment accounted for the highest market stake accounting for approximately 54.3% of the Stargardt disease therapeutics market in 2022. LBS-008, or Tinlarebant, If approved, would offer a cutting-edge therapy alternative where none now exists. To prevent the buildup of harmful vitamin A byproducts in ocular tissue, LBS-008 is an oral once-daily medication that can lower and sustain the distribution of vitamin A (retinol) to the eye.

The capacity of LBS-008 to decrease and maintain the level of serum retinol-binding protein 4, or RBP4, which transports retinol from the liver to the eye, results in this effect. LBS-008 has proven its target specificity and potency in clinical trials, and according to researchers, it may have clinical value for treating Stargardt (STGD1) patients.

Geographical Analysis

The Increasing Number Of Patients with Stargardt disease, and Advancement in Stargardt Disease Therapeutics Dominate The North American Region.

North America is expected to dominate the Stargardt disease therapeutics market, accounting for around 42.7% of this market. This disorder affects about 1 in 10,000 persons. In the United States, there are 30,000 to 200,000 persons who have Stargardt illness. With several academic institutions and research organizations actively pursuing improvements in the field of ophthalmology, North America is a hotspot for scientific research and development. These organizations work together with pharma companies and other stakeholders to provide cutting-edge treatments for Stargardt's illness.

Competitive Landscape

The major global players in the market include: Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., and F. Hoffmann-La Roche AG among others.

Why Purchase the Report?

• To visualize the global Stargardt disease therapeutics market segmentation based on the product, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Stargardt disease therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Stargardt disease therapeutics market report would provide approximately 61 tables, 55 figures, and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing research activities
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of professionals
  • 4.1.3. Opportunity
    • 4.1.3.1. Advancement in therapy
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Drug Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.1.2. Market Attractiveness Index, By Drug Type
• 9.2. LBS-008*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Emixustat

10. By Age Group

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.1.2. Market Attractiveness Index, By Age Group
• 10.2. Children*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Adult

11. By Distribution Channel

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
• 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Kubota Pharmaceutical Holdings Co., Ltd.*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Stargazer Pharmaceuticals Inc
• 14.3. Sanofi S.A.
• 14.4. Alkeus Pharmaceuticals Inc
• 14.5. Astellas Pharma Inc.
• 14.6. CHABiotech CO., Ltd.
• 14.7. ReVision Therapeutics, Inc.
• 14.8. Lin BioScience, Inc.
• 14.9. Biogen Inc.
• 14.10. F. Hoffmann-La Roche AG

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us